Semaglutide — GLP-1 Receptor Agonist (Research Evidence Summary)

Semaglutide is a long-acting analogue of glucagon-like peptide-1 (GLP-1) developed by Novo Nordisk and marketed as Wegovy (chronic weight management), Ozempic (type-2 diabetes), and Rybelsus (oral type-2 diabetes). It has UK MHRA approval for all three indications and is the most widely-used GLP-1 receptor agonist in current clinical practice.

What it is

Semaglutide is a 31-amino-acid peptide analogue of human GLP-1 7-37 with two key modifications that extend its plasma half-life from minutes (native GLP-1) to days: substitution of position-8 alanine with 2-aminoisobutyric acid (resistant to DPP-IV cleavage) and conjugation of a C18 fatty diacid chain at position 26 via a γGlu-2xOEG linker, which binds tightly to circulating albumin and shields the peptide from renal clearance.

The result is a compound with a ~7-day plasma half-life and once-weekly subcutaneous dosing convenience. Oral semaglutide (Rybelsus) is the same molecule formulated with the absorption enhancer SNAC, which permits gastric absorption — the first clinically meaningful oral GLP-1 formulation.

Mechanism of action

Semaglutide binds the GLP-1 receptor with high affinity and activates its Gαs-coupled signalling cascade. Downstream effects include:

• Glucose-dependent insulin secretion from pancreatic β-cells — rises with hyperglycaemia, falls toward baseline at euglycaemia, giving a favourable hypoglycaemia profile vs sulfonylureas or insulin.
• Suppression of glucagon secretion from pancreatic α-cells in hyperglycaemic conditions.
• Slowed gastric emptying — central to the appetite-suppression effect and to the prominent GI side-effect profile.
• Central appetite suppression via vagal afferent and hypothalamic GLP-1 receptors.

See: GLP-1 receptor (glossary), GLP-1 / GIP / glucagon receptor mechanism map.

Human evidence

The clinical evidence base is exceptional by peptide-class standards:

• STEP 1 (Wilding 2021) — semaglutide 2.4 mg weekly in obesity without diabetes: ~15% mean weight loss at 68 weeks.
• STEP 2 (Davies 2021) — semaglutide 2.4 mg in obesity with type-2 diabetes: ~10% mean weight loss at 68 weeks.
• STEP 3, 4, 5, 8 — extensions in different populations and at different timepoints, broadly consistent with the headline STEP 1 result.
• SUSTAIN-1 through SUSTAIN-10 — diabetes-glycaemic-control programme with semaglutide 0.5–1.0 mg weekly; HbA1c reductions of 1.0–1.8% across trial designs.
• SUSTAIN-6 (Marso 2016) — type-2 diabetes cardiovascular outcomes trial; semaglutide reduced major adverse cardiovascular events.
• PIONEER series — oral semaglutide programme; broadly comparable glycaemic efficacy to subcutaneous semaglutide at the appropriate dose.
• SELECT (Lincoff 2023) — semaglutide 2.4 mg in obesity without diabetes but with established cardiovascular disease: reduced major adverse cardiovascular events by ~20% over a median 39.8 months.

This is among the most thoroughly characterised peptide-class evidence bases in medicine.

UK regulatory status

Semaglutide is a UK prescription-only medicine across all three formulations. The MHRA has approved Wegovy for obesity, Ozempic and Rybelsus for type-2 diabetes. NICE has issued guidance on the appropriate populations and prescribing context.

Public-facing UK advertising of semaglutide for weight loss is restricted under POM-advertising rules (Human Medicines Regulations 2012 Regulation 279) and has been actively enforced against in 2024–2026. See: POM advertising rules, weight-loss medicine advertising caution (UK).

Safety signals

• Gastrointestinal symptoms — nausea, vomiting, diarrhoea, constipation. Dose-dependent; usually mitigated by titration.
• Pancreatitis — labelled warning; rare but real.
• Gallbladder disease — slight increase in acute cholecystitis and cholelithiasis in trial populations.
• Diabetic retinopathy — modest increase observed in SUSTAIN-6 in patients with pre-existing retinopathy.
• Medullary thyroid carcinoma — boxed warning derived from rodent C-cell tumour findings; clinical relevance debated.
• Off-label aesthetic / non-indicated use — outside studied populations; safety profile in those contexts is not established.

Off-label and compounded use

Demand for semaglutide has driven a substantial grey market in compounded and unauthorised semaglutide. The MHRA has issued public safety warnings about these sources. Compounded semaglutide is not equivalent to the licensed product; potency, sterility, and formulation cannot be assumed. PeptideStacks does not provide acquisition routes — for any GLP-1 medicine, consult a registered UK prescriber.

Related on this site

• GLP-1 hub
• Tirzepatide evidence summary — the principal head-to-head
• Retatrutide evidence summary
• Tirzepatide vs Semaglutide — evidence comparison
• Triple incretin agonism
• Weight-loss medicine advertising caution (UK)
• Clinical trial evidence vs online claims

Regulatory and clinical status

UK status: UK MHRA approved. Wegovy (semaglutide 2.4 mg weekly SC) is approved for chronic weight management in adults with obesity or overweight with comorbidities. Ozempic (semaglutide 0.5–2 mg weekly SC) is approved for type-2 diabetes. Rybelsus (oral semaglutide) is approved for type-2 diabetes. All formulations are prescription-only medicines (POM).

Read more about how UK regulation applies to peptides in our UK regulation hub and our explanation of what “research use only” means in the UK. PeptideStacks does not make editorial sourcing recommendations within research content; any vendor links elsewhere on this page appear in a clearly-labelled sponsor block (see our conflict-of-interest disclosure).

References

Peer-reviewed sources for the claims above. Where an editor has verified study type, sample size, outcome and limitation, the citation is rendered as a card; otherwise as a plain reference. Links open PubMed or the journal DOI.

Once-Weekly Semaglutide in Adults with Overweight or Obesity

Wilding JPH, Batterham RL, Calanna S, et al. (STEP 1 Investigators) · New England Journal of Medicine · 2021, 384(11), 989-1002

Randomised controlled trialEvidence weight: high

Model

Humans — adults with BMI ≥30 or ≥27 with one weight-related comorbidity, without type-2 diabetes

Sample size

n = 1,961 randomised 2:1 to semaglutide 2.4 mg sc weekly vs placebo

Compound(s)

Semaglutide

Route in study

Subcutaneous, once-weekly, 68 weeks

Outcome measured

Percentage change in body weight from baseline to week 68

Main finding

Mean weight reduction of −14.9% with semaglutide vs −2.4% with placebo at 68 weeks. Approximately 86% of semaglutide participants achieved ≥5% weight loss vs 32% on placebo.

Key limitation

Trial population excluded type-2 diabetes, severe psychiatric illness, and pregnancy. Trial duration 68 weeks — does not establish indefinite use or sustained benefit after discontinuation.

PubMed PMID:33567185

Reported in study context only — not a recommendation or protocol.

Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1)

Sorli C, Harashima SI, Tsoukas GM, et al. (SUSTAIN 1 Investigators) · Lancet Diabetes & Endocrinology · 2017, 5(4), 251-260

Randomised controlled trialEvidence weight: high

Model

Humans — drug-naive adults with type-2 diabetes inadequately controlled on diet and exercise

Sample size

n = 388

Compound(s)

Semaglutide

Route in study

Subcutaneous, once-weekly, 30 weeks

Outcome measured

Change in HbA1c at week 30; weight change

Main finding

HbA1c reduction of −1.45% (0.5 mg) and −1.55% (1.0 mg) vs −0.02% with placebo. Mean weight reduction of 3.7 kg and 4.5 kg vs 1.0 kg with placebo.

Key limitation

Drug-naive type-2 diabetes only; does not generalise to insulin-treated populations or to other indications.

PubMed PMID:28110911

Reported in study context only — not a recommendation or protocol.

1. Marso SP, Bain SC, Consoli A, et al. (SUSTAIN-6 Investigators). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016;375(19) :1834-1844 doi:10.1056/NEJMoa1607141 · PMID: 27633186
2. Aroda VR, Rosenstock J, Terauchi Y, et al. (PIONEER 1 Investigators). PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy. Diabetes Care. 2019;42(9) :1724-1732 doi:10.2337/dc19-0749 · PMID: 31186300
3. Davies M, Færch L, Jeppesen OK, et al. (STEP 2 Investigators). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397(10278) :971-984 doi:10.1016/S0140-6736(21)00213-0 · PMID: 33667417
4. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. (SELECT Trial Investigators). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023;389(24) :2221-2232 doi:10.1056/NEJMoa2307563 · PMID: 37952131

Published: 2026-05-21Last updated: 2026-05-21Last reviewed: 2026-05-21

Pages on PeptideStacks are reviewed when relevant new evidence becomes available. If you spot an error or have new evidence to suggest, please use our corrections policy.